Following its launch in 2000,6 rosiglitazone, the first drug in the “insulin sensitising” thiazolidinedione class, was associated with an increased rate of heart failure.5 This resulted in its withdrawal from Europe, India, New Zealand, and South Africa in 2010-11. This evidence concerns the gene INS and heart failure.